Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Cingulate Inc. Common Stock

CING

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Last trade $4.75
Day change +$0.995 (+26.53%)
Day range $3.66 – $4.93
Volume 1,459,541
Market cap $56M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$56.11M
Price / earnings
—
Price / book
2.7×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.39×

Profitability

Earnings per share
-$1.95
Return on assets
-103.68%
Return on equity
-140.54%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.16×
Current ratio
3.9×
Quick ratio
3.9×
Cash ratio
3.58×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.16M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CING, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.58M$3.93M$5.74M$3.58M$3.15M$1.95M$1.48M$1.88M
Research and development$2.91M$1.49M$2.18M$2M$2.85M$2.7M$2.22M$4.33M
Total operating expenses$7.49M$5.41M$7.92M$5.59M$6M$4.65M$3.71M$6.21M
Operating income-$7.49M-$5.41M-$7.92M-$5.59M-$6M-$4.65M-$3.71M-$6.21M
Interest expense-$171.06K-$141.28K-$536.84K$0-$573.06K-$138.76K-$96.66K$0
Income before taxes-$7.73M-$5.87M-$9.31M-$6.27M-$7.34M-$4.98M-$3.85M-$6.23M
Income taxes$0$0$0$0$0$0$0$0
Net income-$7.73M-$5.87M-$9.31M-$6.27M-$7.34M-$4.98M-$3.85M-$6.23M
Net income attributable to common shareholders-$7.73M-$5.87M-$9.31M-$6.27M-$7.34M-$4.98M-$3.85M-$6.23M
EBITDA-$7.44M-$5.32M-$7.8M-$5.46M-$5.89M-$4.5M-$3.54M-$6.05M
Basic earnings per share-$0.53-$0.45-$0.95-$0.93-$1.35-$1.14-$1.06-$1.87
Diluted earnings per share-$0.53-$0.45-$0.95-$0.93-$1.35-$1.14-$1.06-$1.87

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission

Cingulate Inc. reported Q3 2026 financial results with cash of $23.2 million and announced substantial completion of manufacturing work to address FDA CMC information requests for its lead ADHD drug CTx-1301. The company expects to resubmit the NDA between December 2026 and January 2027. The FDA's Complete Response Letter did not raise safety or efficacy concerns. Net loss for nine months ended September 30, 2026 was $22.9 million, with increased SG&A expenses driven by commercial readiness build-out.

GlobeNewswire Inc.

Cingulate Provides Management Team Update

Cingulate Inc. placed CEO Shane J. Schaffer on administrative leave due to unrelated legal matters. Jennifer Callahan was appointed interim CEO, retaining her CFO role, while board member Jay Roberts became Executive Chairman to ensure business continuity.

GlobeNewswire Inc.

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity Therapeutics announced the appointment of Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience in healthcare and biotech sectors, and will support the company's clinical development of stenoparib, a cancer treatment drug.

GlobeNewswire Inc.

Cingulate Announces Adjournment of Special Meeting

Cingulate Inc. has adjourned its Special Meeting of Stockholders to provide additional time for stockholders to vote on all proposals. The company's Board of Directors continues to believe that the proposals are in the best interests of the stockholders.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 9, 20241-for-12reverse split
Nov 30, 20231-for-20reverse split